Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Price Target from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have received a consensus rating of "Hold" from the seven research firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $22.25.

Several research firms have weighed in on ACRS. HC Wainwright lowered Aclaris Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, January 22nd. StockNews.com lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, April 2nd. BTIG Research restated a "neutral" rating on shares of Aclaris Therapeutics in a report on Thursday, January 11th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of Aclaris Therapeutics in a report on Friday, January 12th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its position in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company's stock worth $299,000 after acquiring an additional 23,747 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Aclaris Therapeutics during the first quarter worth $39,000. BML Capital Management LLC boosted its holdings in Aclaris Therapeutics by 1,338.7% during the first quarter. BML Capital Management LLC now owns 9,395,934 shares of the biotechnology company's stock worth $11,651,000 after purchasing an additional 8,742,827 shares during the last quarter. Octagon Capital Advisors LP bought a new position in Aclaris Therapeutics in the fourth quarter valued at $105,000. Finally, Bain Capital Life Sciences Investors LLC increased its stake in Aclaris Therapeutics by 2.9% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company's stock valued at $3,675,000 after buying an additional 100,000 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Trading Up 3.8 %

Shares of NASDAQ:ACRS traded up $0.05 during trading on Friday, hitting $1.36. 688,182 shares of the company's stock were exchanged, compared to its average volume of 1,459,271. The firm has a market cap of $96.91 million, a P/E ratio of -1.07 and a beta of 0.23. The firm has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.67. Aclaris Therapeutics has a 1-year low of $0.59 and a 1-year high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. The firm had revenue of $17.57 million during the quarter, compared to analyst estimates of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. As a group, research analysts predict that Aclaris Therapeutics will post -0.98 EPS for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.